Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covis Pharma BV

www.covispharma.com

Latest From Covis Pharma BV

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV

Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.

Deals Commercial

Deal Watch: Biogen Picks Up S1P Modulator To Try Competing With Novartis, Celgene

Weeks after immuno-oncology tie-up with Sanofi, Evotec signs a collaboration in fibrotic disease with Pfizer. Epirus expands its biosimilars capabilities with the acquisition of Dutch biotech Bioceros.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q1 2015

In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Covis Pharma SARL
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Covis Pharma BV
  • Senior Management
  • Jack Davis, CEO
    Michael Porter, COO & CFO
  • Contact Info
  • Covis Pharma BV
    Phone: 748 04 04
    Bahnhofstrasse 11
    Zug Branch
    Zug, CH-6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register